1Tavassoli FA, Devilee P. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs [ M ]. Lyon : IARC Press,2003.
2La-Beck NM, Jean GW, Huynh C, et al. Immune checkpoint inhibitors: new insights and current place in cancer therapy [ J ]. Pharmacotherapy, 2015, 35 (10) : 963-976. DOI: 10. 1002/phar. 1643.
3Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009, 361(10) :947-957. DOI: 10. 1056/NEJMoa0810699.
9Yoon N, Do IG, Cho EY. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistoehemieal tests and manual FISH [ J ]. APMIS, 2014, 122 ( 9 ) : 755-760. DOI: 10. llll/apm. 12215.
10Watanabe M, Kawaguehi T, Isa S, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR[ J]. Clin Cancer Res, 2015, 21 ( 15 ) : 3552-3560. DOI : 10.1158/1078-0432. CCR-14-2151.
7Dietel M, Sers C. Personalized medicine and development of targeted therapies : the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch, 2006, 448 (6) :744-755.
8Watson MA, Perry A, Budhraja V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res, 2001,61 (5) : 1825-1829.
9Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 2001,98(24) :13790-13795.
10Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol, 2001, 159(4) :1231-1238.
